

Docket No. 58075-Z/JPW/GJG/JAS

Applicant(s): Ridwan Shabsigh

Serial No. : 10/658,991 Examiner: R. M. Kelly

Filed : September 9, 2003 Group Art Unit: 1633

For : USES OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE TREATMENT  
OF ERECTILE DYSFUNCTION

Mail Stop Amendment  
COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

Date: September 11, 2007

Sir:

Transmitted herewith is an amendment to the above-identified application.

X Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been previously established.

       A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27 is enclosed.

X No additional fee is required.

The filing fee is calculated as follows:

	Number after Amendment	Highest Number Previously Paid For <sup>1</sup>	Number of Extra Claims Presented	RATE			FEE	
				Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	12 -	* 20 =	*** 0 X	\$25	\$50	=	0	
Independent Claims	3 -	** 3 =	*** 0 X	\$100	\$200	=	0	
Multiple Dependent Claim(s) Presented For First Time <u>      </u> Yes <u>X</u> No				\$180	\$360	=	0	
				TOTAL ADDITIONAL FEE			\$ 0	

<sup>1</sup> The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims originally filed.

\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\* If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0".

Applicant(s): Ridwan Shabsigh

Serial No. : 10/658,991

Filed : September 9, 2003

Amendment Transmittal Letter

Page 2

The following are also enclosed:

☒ One additional copy of this Amendment Transmittal Letter

☒ Return Receipt Postcard

☐ An Information Disclosure Statement, including Form PTO-1449

(Copies of citations included: Yes ☐ No ☐

and a fee of \$ ☐ included)

☐ A Petition for an Extension of Time, including a fee of  
\$ ☐ for a Petition for ☐ Month(s) Extension of Time

☐ Other (identify): ☐

THE TOTAL FEE DUE IS \$ ☐ 0 ☐.

☒ A check in the amount of \$ ☐ 0 ☐ is enclosed.

☐ Please charge Deposit Account No. ☐ in the amount of  
\$ ☐.

☒ The Commissioner is hereby authorized to charge any additional fees  
required or credit any overpayment to Deposit Account No. 03-3125  
as follows:

☒ Fees under 37 C.F.R. §1.16 for the presentation of extra claims  
☐ Patent application processing fees under 37 C.F.R. §1.17

Respectfully submitted,

I hereby certify that this  
correspondence is being deposited this  
date with the U.S. Postal Service with  
sufficient postage as first class mail  
in an envelope addressed to:  
Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450.

Gary J. Gershik  
Gary J. Gershik  
Reg. No. 39,992

Date

Gary J. Gershik  
John P. White

Registration No. 28,678

Gary J. Gershik

Registration No. 39,992

Attorneys for Applicant(s)

Cooper & Dunham LLP (Customer #23432)

1185 Avenue of the Americas

New York, New York 10036

(212) 278-0400



Dkt. 58075-Z/JPW/GJG/JAS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ridwan Shabsigh  
U.S. Serial No.: 10/658,991 Examiner: Robert M. Kelly  
Filing Date : September 9, 2003 Group Art Unit: 1633  
For : USES OF VASCULAR ENDOTHELIAL GROWTH FACTOR  
IN THE TREATMENT OF ERECTILE DYSFUNCTION

1185 Avenue of the Americas  
New York, New York 10036  
September 11, 2007

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

AMENDMENT IN RESPONSE TO JUNE 13, 2007 OFFICE ACTION

This Amendment is submitted in response to the June 13, 2007 Office Action issued by the United States Patent and Trademark Office in connection with the above-identified application. A response to the June 13, 2007 Office Action is due September 13, 2007. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

**Amendments to the claims** begin on page 3 of this paper.

**Remarks** begin on page 5 of this paper.